HARBOUR BIOMED PARTNER, SOLSTICE ONCOLOGY, ANNOUNCES $225 MILLION SERIES A FINANCING TO ADVANCE PORUSTOBART, A NEOADJUVANT IMMUNO-ONCOLOGY THERAPY

Reuters · 1d ago

Please log in to view news